Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
17 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Scemblix“
Suchtreffer
Begriffe & Kennungen
Scemblix · 4.8 · Neutropenia occurred in 16.7% of patients with the T315I mutation receiving asciminib, with grade 3 and 4 reac
Eintrag öffnenScemblix · 4.8 · Neutropenia occurred in 21.8% of patients receiving asciminib, with grade 3 and 4 reactions reported in 7.6% a
Eintrag öffnenScemblix · 4.8 · Pancreatic toxicity Pancreatitis occurred in 2% of patients receiving asciminib, with grade 3 reactions occurr
Eintrag öffnenScemblix · 4.8 · Pancreatitis occurred in 2.1% of patients with the T315I mutation receiving asciminib. Elevations of serum lip
Eintrag öffnenScemblix · 4.8 · Ph+ CML (ASCEMBL, X2101, ASC4FIRST studies) The most common adverse reactions of any grade (incidence ≥20%) in
Eintrag öffnenScemblix · 4.8 · Ph+ CML-CP with the T315I mutation in patients resistant to, intolerant to or ineligible for ponatinib (X2101
Eintrag öffnenScemblix · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenScemblix · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenScemblix · 4.8 · Serious adverse reactions occurred in 12.5% of patients receiving asciminib. The most frequent serious adverse
Eintrag öffnenScemblix · 4.8 · Serious adverse reactions occurred in 9.9% of patients receiving asciminib. The most frequent serious adverse
Eintrag öffnenScemblix · 4.8 · Summary of the safety profile
Eintrag öffnenScemblix · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenScemblix · 4.8 · The most common adverse reactions of any grade (incidence ≥20%) in patients receiving asciminib were musculosk
Eintrag öffnenScemblix · 4.8 · The most common adverse reactions of ≥ grade 3 (incidence ≥5%) in patients receiving asciminib were thrombocyt
Eintrag öffnenScemblix · 4.8 · The most common adverse reactions of ≥grade 3 (incidence ≥5%) in patients receiving asciminib were increased p
Eintrag öffnenScemblix · 4.8 · The overall safety profile of asciminib has been evaluated in 556 patients with Ph+ CML in chronic (CP) and ac
Eintrag öffnenScemblix · 4.8 · Thrombocytopenia occurred in 20.8% of patients with the T315I mutation receiving asciminib, with grade 3 and 4
Eintrag öffnen